ArticleBMJ public health2026
Hypertension prevalence, detection, treatment and control among 1.4 million adults in England: a cross-sectional analysis from the Our Future Health study in 2022-2025.
Article in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To assess the prevalence, detection, treatment and control of hypertension in England. Design: Cross-sectional analysis of baseline blood pressure measurements from the Our Future Health study. Setting: Over 200 enrolment centres across England, 2022-2025. Participants: 1.4 million adults aged ≥18 years with available clinic blood pressure measurements. Main outcome measures: Hypertension was defined according to WHO guidelines as systolic blood pressure (SBP) ≥140 mm Hg, diastolic blood pressure (DBP) ≥90 mm Hg or self-reported use of antihypertensive medication. Detection was defined as self-reported prior diagnosis by a health professional or reported use of antihypertensive medication. Controlled hypertension was defined as SBP <140 mm Hg and DBP <90 mm Hg among those receiving antihypertensive treatment. Results: Overall, 37.2% of participants had hypertension, with higher age-standardised prevalence in men than women (41.9% vs 28.6%). Prevalence increased markedly with age, from 23% to 73% in men and from 10% to 69% in women at ages 18-39 and ≥80 years, respectively. Despite this high burden, 58.8% of individuals with hypertension were undetected. Hypertension was strongly associated with older age, male sex and higher body mass index, but the prevalence remained substantial across all population subgroups. Factors associated with hypertension detection largely mirrored those associated with hypertension, except in individuals with prior cardiovascular disease or diabetes, among whom detection was higher. Among detected participants, antihypertensive treatment was associated with lower odds of uncontrolled blood pressure; however, 50.2% of treated individuals did not achieve blood pressure control. Conclusions: Over one-third of adults in England had hypertension, yet only half of affected individuals were detected and half of those treated achieved blood pressure control. The high prevalence across nearly all population subgroups underscores the need for population-wide prevention strategies alongside targeted treatment of individuals at high cardiovascular risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.